A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer – GI03-53

For full description, see www.clinicaltrials.gov.

Abstracts/Posters/Presentations:

• Chiorean EG, Schiel M, Sanghani S, Yu M, Shen J, Cardenes H, LeBlanc J, Robb B, Loehrer PJ, Harvey J: A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53. Accepted as Poster Presentation at the ASCO GI Symposium, January 25-27, 2008, Orlando, FL
• Chiorean EG, Schiel M, Sanghani S, Yu M, Shen J, Cardenes H, LeBlanc J, Robb B, Loehrer PJ, Harvey J: A Phase II trial of Neoadjuvant Capecitabine plus Irinotecan Followed by Combined Modality Capecitabine and Radiation Therapy for Patients with Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53. Poster Presentation at Indiana University Melvin and Bren Simon Cancer Center Cancer Research Day, May 7, 2008

Manuscripts/Articles:

• Cardenes, H., Sanghani, S., Burns, M., Robb, B., Hinkle, D., Johnson, C., Yu, M., Currie, C., Loehrer, P., Chiorean, E. Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC): A Hoosier Oncology Group Study GI03-53. International Journal of Radiation Oncology*Biology*Physics. Volume 78, Issue 3, Supplement, Page S54, 1 November 2010. doi:10.1016/j.ijrobp.2010.07.160
• Chiorean EG, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemother Pharmacol. 2012 Jul;70(1):25-32. doi: 10.1007/s00280-012-1883-1. Epub 2012 May 18. See abstract.